A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects - Trial NCT03929172
Access comprehensive clinical trial information for NCT03929172 through Pure Global AI's free database. This Phase 1 trial is sponsored by 2A Pharma AB and is currently Completed. The study focuses on Papillomavirus Infections. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
2A Pharma AB
Timeline & Enrollment
Phase 1
Feb 28, 2019
May 29, 2020
Primary Outcome
Percentage of Subjects Reporting Solicited Local Symptoms,Percentage of Subjects Reporting Solicited General Symptoms,Percentage of Subjects Reporting Unsolicited Adverse Events (AEs),Percentage of Subjects Reporting New Onset of Chronic Illness (NOCI),Percentage of Subjects Reporting Adverse Events of Special Interest (AESI),Percentage of Subjects Reporting Serious Adverse Events (SAEs),Vital Signs - Body Temperature,Vital Signs - Respiratory Rate,Vital Signs - Blood Pressure,Vital Signs - Heart Rate,Vital Signs - Body Mass Index (BMI,Electrocardiogram (ECG),Physical examination,Clinical Laboratory Tests
Summary
The purpose of this study is to evaluate the safety, tolerability, and the immunological
 effects of adeno-associated virus-like particle human papillomavirus (AAVLP-HPV) vaccine in
 healthy adults.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03929172
Non-Device Trial